Abstract
The levels of the antibody response against SARS-CoV-2 varies widely between individuals, which together with the decline of antibody responses over time, complicates the correct classification of seropositivity using conventional assay cut-offs. All subjects in a cohort of SARS-CoV-2 PCR+ individuals representing different disease severity categories (n=105), and a group of PCR+ hospital staff (n=33), developed IgG against pre-fusion-stabilized spike (S) trimers and 97% did against the receptor-binding domain (RBD). The levels differed by several orders of magnitude and associated with disease phenotype. Concomitant analysis of a cohort of healthy blood donors and pregnant women (n=1,000), representing individuals who had undergone milder infections, demonstrated highly variable IgG titers, including several that scored between the classical 3SD and 6SD cut-offs. Since the correct classification of seropositivity is critical for epidemiological estimates, we trained probabilistic algorithms to assign likelihood of past infection using anti-S and -RBD IgG data from PCR+ individuals and a large cohort of historical negative controls (n=595). Applied to blood donors and pregnant women, this probabilistic approach provided a more accurate way to interpret antibody titers spread over a large continuum offering a probability-based diagnosis. The methods described here are directly applicable to serological measurements following natural infection and vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this work was provided by a Distinguished Professor grant from the Swedish Research Council (agreement 532 2017-00968) and NIH (agreement SUM1A44462-02). CW and NFG are funded by the Wellcome Trust (WT107881) and MRC (MC_UP_1302/5)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Swedish Ethical Review Authority (registration no. 2020-01807).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data generated as part of the study, along with custom code for statistical analyses, is openly available via our GitHub repositories: https://github.com/MurrellGroup/DiscriminativeSeroprevalence/ and https://github.com/chr1swallace/seroprevalence-paper.
